Polycyclo Ring System Patents (Class 514/510)
-
Publication number: 20100130545Abstract: The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.Type: ApplicationFiled: April 25, 2008Publication date: May 27, 2010Inventors: Kurt Hilpert, Francis Hubler, Dorte Renneberg
-
Publication number: 20100119482Abstract: Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.Type: ApplicationFiled: December 24, 2009Publication date: May 13, 2010Inventors: Anthony Joonkyoo Yun, Partic Yuarn-Bor Lee
-
Publication number: 20100120907Abstract: Provided are topical formulations comprising an Amyris alcohol and/or ester derivatives of Amyris alcohol which may be used for the treatment of diseases including herpes virus infection (e.g., HSV-1, HSV-2), epidermoid carcinoma, cold sores, and human papillomavirus. Amyris alcohols contemplated for use with the present invention include valerianol, beta-eudesmol, epi-gamma-eudesmol, elemol, alpha-eudesmol, and ester derivatives thereof.Type: ApplicationFiled: April 18, 2008Publication date: May 13, 2010Inventors: Chandra Ulagaraj Singh, Rao Jagaveerabhadra Nulu
-
Patent number: 7713939Abstract: The present invention provides illudin analogs of the general formula (I): where R1 is (CH2)n—X—Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C1-C8)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl or cyclo(C3-C6)alkyl optionally comprising one or more heteroatoms; a monosaccharide, an amino acid residue, or H when n is 2-4; R2 is absent; or R1 and R2 together comprise a 5-7 membered cyclic ring; R3 is (C1-C4)alkyl or H; R4 is H, SCH2CO2(C1-C4)alkyl, O—(C5-C12)aryl or —S—(C5-C12)aryl; R5 is H, OH or absent; R6 is (C1-C4)alkyl or absent; R7 is OH or OSi((C1-C4)alkyl)3; or R6 and R7 together are ethylenedioxy; R8 is optionally substituted (C1-C4)alkyl; and the bonds represented by ----- are individually present or absent. The invention further provides dimers comprising analogs of formula (I).Type: GrantFiled: December 12, 2007Date of Patent: May 11, 2010Assignee: The Regents of The University of CaliforniaInventors: Trevor C. McMorris, Michael J. Kelner
-
Publication number: 20100105637Abstract: The invention involves sustained-release pharmaceutical compositions containing a water-soluble ionic small molecule pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be formulated into sustained-release pharmaceutical compositions.Type: ApplicationFiled: October 22, 2009Publication date: April 29, 2010Inventor: Cherng-ju Kim
-
Publication number: 20100093852Abstract: The present invention relates to a composition comprising shikonin compounds, especially, isobutyryl shikonin, ?-?-dimethylacryl shikonin, isovaleryl shikonin, and ?-methyl-n-butyryl shikonin as an active ingredient for the prevention and treatment of diabetes mellitus and the use thereof. The composition of the present invention showed stimulating effect on the release of insulin in the beta cell of the pancreas due to inhibitory effect on KATP ion channel of beta cell in pancreas together with promoting effect on the increase of calcium concentration. Therefore, it can be used as the therapeutics, health functional food or food additive for treating and preventing diabetes mellitus.Type: ApplicationFiled: December 12, 2006Publication date: April 15, 2010Inventors: Ji Ho Park, Sun Yeou Kim, Tong Ho Kang, Eun Ju Hwang, Chul Hoon Kang
-
Publication number: 20100086602Abstract: The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.Type: ApplicationFiled: August 30, 2007Publication date: April 8, 2010Inventor: Kensuke Egashira
-
Patent number: 7674827Abstract: Indanyl- and Tetrahydronaphtyl-amino-thiourea compounds for combating animal pests The present invention relates to Indanyl- and Tetrahydronaphtyl-amino-thiourea compounds of formula I wherein the variables R1 to R4 are as in the description. The invention relates also to methods of combating or controlling insects, arachnids or nematodes, to methods for protecting growing plants from attack or infestation by insects, arachnids or nematodes, to methods for the protection of seeds from soil insects and of the seedlings' roots and shoots from soil and foliar insects and to methods for treating, controlling, preventing or protecting animals against infestation or infection.Type: GrantFiled: November 15, 2006Date of Patent: March 9, 2010Assignee: BASF SEInventors: Markus Kordes, Christopher Koradin, Deborah L. Culbertson
-
Publication number: 20100056615Abstract: The present invention refers to the use of at least one tricyclic diterpenes for the manufacture of a nutraceutical or pharmaceutical for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders.Type: ApplicationFiled: November 21, 2007Publication date: March 4, 2010Inventors: Daniel Raederstorff, Goede Schueler, Joseph Schwager, Christof Wehrli
-
GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF
Publication number: 20100035983Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: July 9, 2009Publication date: February 11, 2010Applicants: CELERA CORPORATION, UNIVERSITY OF TEXAS BOARD OF REGENTSInventors: Dov SHIFFMAN, James J. DEVLIN, Judy Z. LOUIE, Eric BOERWINKLE -
Publication number: 20100022461Abstract: Disclosed is tonovel cyclic derivatives having potent inhibiting effect on melanin formation and skin hyper-pigmentation activity with no adverse response to skin. They can be used as the therapeutics for treating and preventing the skin disease caused by over-reproduced melanin.Type: ApplicationFiled: July 2, 2007Publication date: January 28, 2010Applicant: WONKISOPHARM CO., LTD.Inventors: Hyun Chul Cho, Yonghyun Choi, Jonghan Yhei
-
Publication number: 20100004190Abstract: This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.Type: ApplicationFiled: August 14, 2009Publication date: January 7, 2010Applicant: PACIFIC ARROW LIMITEDInventors: Pui-Kwong CHAN, May Sung MAK
-
Publication number: 20090306203Abstract: The present invention relates to Compounds of general formula (I), wherein R is hydrogen and R1 is hydroxy or acyloxy, or R is acyl and R1 is hydroxy or acyloxy, X is sulphur, oxygen or NR10, wherein R10 is hydrogen or (C1-4)alkyl; Y is sulphur or oxygen; R2 is hydrogen or one or more substituents, e.g. including substituents such as conventional in organic, e.g. (pleuro)mutilin, chemistry; R4 is hydrogen or (C1-4)alkyl; R5 is hydrogen or (C1-4)alkyl; R3 and R3? are hydrogen, deuterium, or halogen; R6, R7 and R8 are hydrogen, halogen or deuterium; m is a number selected from 0 to 4, n is a number selected from 0 to 10, and p is a number selected from 0 to 10; with the proviso that n plus p are at least 1. These Compounds are usefül as pharmaceuticals, particularly as antimicrobials.Type: ApplicationFiled: June 26, 2006Publication date: December 10, 2009Applicant: Nabriva Therapeutics Forschungs GmbHInventors: Rosemarie Mang, Gerd Ascher, Mathias Ferencic, Werner Heilmayer, Rodger Novak
-
Patent number: 7625947Abstract: This invention relates to novel AKBA analogs of the formula I given below: Where in R1, R2, R3, R4 and R5 in each of the said analogs are: 1. R1?OCHO, R2?H, R3?COOH, R4 & R5?O 2. R1?OCOCH2Cl, R2?H, R3?COOH, R4 & R5?O 3. R1?5?-O-methylgalloyloxy, R2?H, R3?COOH, R4 & R5?O 4. R1?OCOCH2CH2COOH, R2?H, R3?COOH, R4 & R5?O 5. R1?8?,9?-Dihydro-4?-hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 6. R1?4?-Hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 7. R1?3?,4?-Dimethoxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 8. R1?3?,4?-Dihydroxy-5?-methoxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 9. R1?OCOCH2NH(tert-BOC), R2?H, R3?COOCH3, R4 & R5?O 10. R1?OCOCH2NH2HCl, R2?H, R3—COOH, R4 & R5?O 11. R1?OCOCH(CH3)NH2HCl, R2?H, R3?COOH, R4 & R5?O 12. R1?H, R2?OH, R3?COOCH3, R4 & R5?O 13. R1?H, R2?Br, R3 COOCH3, R4 & R5?O 14. R1?CN, R2?H, R3?COOCH3, R4 & R5?O 15. R1?SH, R2?H, R3?COOCH3, R4& R5?O 16. R1 & R2?N(OH), R3?COOCH3, R4 & R5?O 17.Type: GrantFiled: June 18, 2004Date of Patent: December 1, 2009Assignee: Laila NutraceuticalsInventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Subbaraju Gottumukkala, Trimurtulu Golakoti
-
Publication number: 20090292016Abstract: Stabilized pharmaceutical preparations containing a drug which is sensitive to a low pH environment, such as pravastatin are disclosed in which pravastatin degradations is prevented with a buffering agent. The basic excipient enhances storage stability.Type: ApplicationFiled: July 31, 2009Publication date: November 26, 2009Inventors: Boyong Li, Avinash Nangia, Aaron Dely, David Wong
-
Patent number: 7622506Abstract: This invention relates to compositions containing a compound of formula (I) shown below: Each variable is defined in the specification. Also disclosed are methods of using these compositions to treat acne, psoriasis, and infective skin ulcer.Type: GrantFiled: April 9, 2007Date of Patent: November 24, 2009Assignee: SunTen Phytotech Co., Ltd.Inventors: Du-Shieng Chien, Yi-Wen Chu, Wu-Chang Chuang, Ming-Chung Lee
-
Publication number: 20090214435Abstract: A recombinant vector capable of expressing MDR1 shRNA and thymidine kinase, and a use thereof. More specifically, provided is a recombinant vector capable of efficiently expressing MDR1 shRNA and thymidine kinase in a host cell, a transfectant cell comprising the same recombinant vector, a composition for treating neoplastic diseases, comprising the same recombinant vector, and a method for imaging of neoplastic lesions using the same recombinant vector. The recombinant vector of the present invention is capable of achieving efficient intracellular expression of MDR1 shRNA and a thymidine kinase-GFP fusion protein within the host cell and is therefore highly effective for combined therapy of anticancer drugs. Further, the recombinant vector of the present invention enables imaging of neoplastic lesions. Therefore, the recombinant vector of the present invention can be used in combination with other anticancer drugs for treatment of neoplastic diseases.Type: ApplicationFiled: March 18, 2008Publication date: August 27, 2009Inventors: In San Kim, Seung Yoon Park, Jae Tae Lee, Byeong Cheol Ahn
-
Publication number: 20090215687Abstract: The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 3,6-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride, 2,8-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate, tilorone analogue R-9536-DA, indoprofen, ciclopiroxolamine, tryptophan, ansindione, nabumetone, oxybendazole, albendazole, tropicamide, pramoxine hydrochloride, atenolol, mebendazole, carbetapentane citrate, monensin sodium, methoxyvone, hydroxyzine, phenazopyridine, clofoctol, ipraflavone, zomepirac, biochanin A, xylometazoline hydrochloride, fenbendazole, pirenzepine, triprolidine hydrochloride, daidzein, tripelennamine citrate, colchicines, aminopyridine, trimethoprim, helenine, hydroxyurea, amiodarone hydrochloride, clindamycin hydrochloride, sulfachlorpyridazine, mephenesin, semustine, clofivric acid, clofibrate, ibuprofen, hyoscyamime, nafcillin sodium, piperin, clidinium bromide, trioxsalen, hydralazine aType: ApplicationFiled: October 20, 2006Publication date: August 27, 2009Applicant: CORNELL RESEARCH FOUNDATION, INC.Inventors: Rajiv R. Ratan, Ambreena Siddiq, Juan C. Chavez
-
Publication number: 20090214508Abstract: The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells thereby inhibiting VEGF activation of VEGF receptors and inducing apoptosis in the tumor cells. Fusion proteins of the present invention are useful for inducing apoptosis and cytotoxic effects in cells, treating cancer and diseases or disorders related to unregulated angiogenesis and/or vasculogenesis. Thus, this invention further provides methods for treating angiogenesis related diseases using the fusion proteins, polynucleotides encoding the fusion proteins, vectors containing the polynucleotides, pharmaceutical compositions and kits containing the fusion proteins or the polynucleotides encoding the fusion proteins.Type: ApplicationFiled: August 15, 2006Publication date: August 27, 2009Applicant: REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Timothy P. Quinn
-
Publication number: 20090186940Abstract: A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's diseases, etc. The invention provides for the synthesis of scabronines as well as analogs thereof. Pharmaceutical compositions and method of using the inventive compounds are also provided.Type: ApplicationFiled: January 22, 2008Publication date: July 23, 2009Inventors: Samuel J. Danishefsky, Stephen P. Waters
-
Publication number: 20090182045Abstract: The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration.Type: ApplicationFiled: April 10, 2007Publication date: July 16, 2009Applicant: FONDAZIONE IRCCS ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO DI NATURAInventor: Raffaella Scorza
-
Publication number: 20090181150Abstract: This invention provides compositions and methods for producing low cholesterol poultry eggs using hypocholesterolemic compounds, cholesterol lowering supplements, and feeds therefrom. Preferably, this invention provides microbial statins without methyl group in C6, as shown in formula V, in order to produce low cholesterol poultry eggs. The invention allows producing low cholesterol poultry eggs without concomitant reduction of egg production by providing microbial statins, compactin and pravastatin as well as their derivatives, as cholesterol lowering components. This invention also provides methods for producing low cholesterol poultry eggs without huge increase of production cost since the effective amount of cholesterol lowering composition containing microbial statin costs 1/20-¼ of that of synthetic statin.Type: ApplicationFiled: December 10, 2004Publication date: July 16, 2009Inventors: Jeong hak Kim, Hyeon jin Kim, Seong tshool Hong
-
Publication number: 20090156515Abstract: This invention provides composition comprising a triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin, comprising at least two side groups selected from the group consisting of: angeloyl groups, tigloyl groups and senecioyl groups, wherein the side groups are attached to carbon 21, 22 or/and 28 of triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin backbone. This invention provides a composition for inhibiting tumor cell growth, comprising an appropriate amount of a triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin, wherein the triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin comprises any two side groups selected from the group consisting of: angeloyl groups, tigloyl groups and senecioyl groups, wherein the side groups are attached to carbon 21, 22 or/and 28 of triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin backbone.Type: ApplicationFiled: December 29, 2008Publication date: June 18, 2009Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
-
Publication number: 20090117040Abstract: The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases.Type: ApplicationFiled: February 11, 2005Publication date: May 7, 2009Applicant: Max-Delbrug-Centrum Fur Molekulare MedizinInventors: Erich Wanker, Sabine Engemann, Susanne Rautenberg, Annett Boeddrich, Phoebe Markovic, Dagmar Ehrnhofer, Martin Herbst, Jacqueline Walther
-
Publication number: 20090088472Abstract: An object of the present invention is to provide a protective agent for a neuronal cell. The protective agent for a neuronal cell according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, R1, R2 and R3 are the same or different and represent a hydrogen atom or an alkyl group, or R1 and R3 may be joined together to form a ring having one or more double bonds.Type: ApplicationFiled: May 17, 2006Publication date: April 2, 2009Inventors: Kouji Oohashi, Reina Doi, Masaaki Kageyama
-
Publication number: 20090076032Abstract: The present invention relates to novel derivatives of 18?-glycyrrhetinic acid and methods of synthesising the derivatives. Also included within the scope of the present invention are pharmaceutical compositions comprising the derivatives of the present invention and medical uses of the derivatives, including their use in inhibiting enzymes such as retinol dehydrogenases. The present invention also relates to methods of treating diseases, such as hyperproliferative diseases, neoplasms, cancers and photoageing.Type: ApplicationFiled: September 10, 2008Publication date: March 19, 2009Inventors: Simon Ward, Alice Macgowan, Stanley Roberts, Jenny Littlechild, Kirsty Line, Ed Irving, Sam Donnelly
-
Patent number: 7501455Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: GrantFiled: March 17, 2004Date of Patent: March 10, 2009Assignee: Sicor, Inc.Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Patent number: 7491847Abstract: A process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan, a process for isolating from a reaction mixture a crystalline diastereomeric salt of a mono-propargylated aminoindan, and a process for isolating from a reaction mixture a salt of enantiomerically pure N-propargyl-1-aminoindan or a salt of enantiomerically pure 6-(N-methyl, N-ethyl-carbamoyloxy)-N?-propargyl-1-aminoindan. The corresponding products are also disclosed.Type: GrantFiled: November 15, 2006Date of Patent: February 17, 2009Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Anton Frenkel, Ramy Lidor-Hadas, Eduard Gurevich, Gsan Attili
-
Patent number: 7488753Abstract: This invention provides composition comprising a triterpenoidal saponin, comprising two side groups attached to carbon 21, and 22 of triterpenoidal saponin backbone. This invention provides a composition for inhibiting skin or ovarian tumor cell growth, comprising an appropriate amount of said compound.Type: GrantFiled: November 28, 2005Date of Patent: February 10, 2009Assignee: Pacific Arrow LimitedInventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
-
Publication number: 20090036524Abstract: The present invention relates to the use of triterpenes of the formula (I): which are inhibitors of nuclear factor kappa B (NF-KB for use in the treatment of inflammatory diseases and for cancers susceptible to an NF-KB inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.Type: ApplicationFiled: March 1, 2007Publication date: February 5, 2009Inventors: Inderjit Kumar Dev, Ven Subbiah
-
Publication number: 20090030075Abstract: A drug for alleviating bleeding tendency caused by a thrombus removing means comprising, as an active ingredient, a compound represented by formula (I): (wherein R1 represents hydrogen or a metabolic ester residue, R2 represents hydrogen or —R3—R4 (wherein R3 represents —SO3—, —CH2COO—, —COCOO— or —COR5COO— (wherein R5 represents lower alkylene or lower alkenylene), and R4 represents hydrogen or a metabolic ether residue)), or a pharmaceutically acceptable salt thereof, or a solvate thereof.Type: ApplicationFiled: December 20, 2006Publication date: January 29, 2009Inventors: Mitsuyoshi Ninomiya, Toshiaki Nagafuji
-
Publication number: 20080318788Abstract: A microcapsule comprising an active component encapsulated therein, and comprising a particulate matter located in a wall thereof to render the wall permeable. Such microcapsules can be used in a variety of applications including agrochemical applications, which are also described and claimed.Type: ApplicationFiled: January 19, 2006Publication date: December 25, 2008Inventor: Allan Kunamoney Nadian
-
Publication number: 20080286264Abstract: The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either p53 or TBP. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of MUC1 by a cell.Type: ApplicationFiled: February 14, 2006Publication date: November 20, 2008Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventor: Donald W. Kufe
-
Publication number: 20080280932Abstract: The disclosure provides methods and compositions for the treatment of vascular, autoimmune and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor.Type: ApplicationFiled: July 10, 2008Publication date: November 13, 2008Inventors: Michael R. Hayden, Noel Hall
-
Publication number: 20080260718Abstract: The present invention provides methods of preventing and treating pain, by modulating, e.g. inhibiting, the activity, function and/or expression of a PLC? in a subject. The invention further relates to methods of identifying agents capable of modulating the activity and/or expression of a PLC?, or capable of modulating binding of a ligand or binding partner to a PLC?, and their use thereof for the prevention and/or treatment of pain. In a further aspect, the invention provides methods for the diagnosis and prognostication of pain by determining whether there is modulation of activity and/or expression of a PLC? relative to a corresponding control.Type: ApplicationFiled: May 13, 2005Publication date: October 23, 2008Inventors: Jeffrey A.M. Coull, Yves De Koninck
-
Patent number: 7435756Abstract: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like.Type: GrantFiled: February 12, 2004Date of Patent: October 14, 2008Assignee: Australian Biomedical Company Pty, Ltd.Inventors: Peter James Jenkins, Minnie Wu, David Shine Wu
-
Patent number: 7435755Abstract: CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.Type: GrantFiled: November 28, 2001Date of Patent: October 14, 2008Assignees: The Trustees of Dartmouth College, Board of Regents, The University of Texas SystemInventors: Marina Konopleva, Michael Andreeff, Michael B. Sporn
-
Publication number: 20080248139Abstract: The invention relates to a process for the preparation of ferutinine (Ia) from Ferula spp extracts comprising basic hydrolysis of the extracts and treatment with p-pivaloyloxybenzoic acid. The invention relates also to the use of the extracts and ferutinine in the cosmetic and dermatological field.Type: ApplicationFiled: March 31, 2008Publication date: October 9, 2008Applicant: INDENA S.P.A.Inventors: Ezio Bombardelli, Gabriele Fontana, Aldo Cristoni, Enrico Mercalli
-
Patent number: 7407985Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: GrantFiled: January 17, 2006Date of Patent: August 5, 2008Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Patent number: 7384977Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.Type: GrantFiled: August 31, 2006Date of Patent: June 10, 2008Assignee: PG-TXL Company, L.P.Inventors: Chun Li, Sidney Wallace, Dong-Fang Yu, David J. Yang
-
Patent number: 7378442Abstract: The invention relates to methods of treatment and pharmaceutical compositions of new chemical compounds that inhibit the various enzymes in the arachidonic acid pathway implicated in inflammatory disease conditions.Type: GrantFiled: October 12, 2007Date of Patent: May 27, 2008Assignee: Sami Labs LimitedInventors: Muhammed Majeed, Kalyanam Nagabushnam, Rajendran Ramanujam, Subbalakshmi Prakash
-
Patent number: 7371780Abstract: Calphostin C is used to treat subjects for cancer which is resistant to treatment by other forms of chemotherapeutic drugs, for example breast or uterine cancer, or other cancers characterized by tumor cells that have a defect in an apoptotic regulatory pathway which renders said cells resistant to at least some other forms of chemotherapeutic treatment. The other chemotherapeutic drug used with calphostin C is selected from the group comprising taxanes and anthracyclines, such as paclitaxel or doxorubicin. The use may take the form of administering calphostin C and then subjecting the patient to photodynamic therapy (PDT).Type: GrantFiled: October 27, 2004Date of Patent: May 13, 2008Inventor: Amadeo Parissenti
-
Patent number: 7348449Abstract: Novel ligand antagonists of the RAR receptors have the following structural formula (I): in which A is a CH2, CHOH, C?O or C?N—OH radical or a sulfur or selenium atom; B is a radical selected from among those of formulae (a) to (f): and Ar is a radical selected from among those of formulae (g) to (i):Type: GrantFiled: April 28, 2005Date of Patent: March 25, 2008Assignee: Galderma Research & DevelopmentInventors: Philippe Diaz, Catherine Raffin, Thibaud Biadatti
-
Patent number: 7314637Abstract: Liposomal-encapsulated taxane or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer. The liposomal encapsulated paclitaxel allows for administration to a patient, particularly a human patient, in less than one hour without substantial toxicity.Type: GrantFiled: June 29, 1999Date of Patent: January 1, 2008Assignee: Neopharm, Inc.Inventor: Aquilar Rahman
-
Patent number: 7297691Abstract: The present invention is concerned with treatment of sleep disorders by administering a cholinesterase inhibitor, and in particular, by administering galantamine or a pharmaceutically acceptable salt thereof. Also in particular, cholinesterase inhibitors that are active at nicotinic receptors and that are selective for acetylcholinesterase over butylcholinesterase are used in treating sleep disorders.Type: GrantFiled: August 11, 2004Date of Patent: November 20, 2007Assignee: Janssen Pharmaceutica N.V.Inventor: Michael Gold
-
Patent number: 7268162Abstract: The invention relates to aloe-emodin (AE) derivatives and their use as anticancer drugs. Saids derivatives show a specific cytotoxicity to tumour cells, also of neuroectodermal origin, to which they may in particular act as aloe-emodin prodrugs. Said pharamcological profile makes them particularly suitable for use in the treatment of neoplasias. Thereofore, pharmaceutical compositions containing said compound may be usefully used in the treatment of neoplasias. It has surprisingly been found that aloe-emodin derivatives in position 3? (bearing either a positive or negaive charge) exhibit improved sollubility properties and, at the same time, in vitro show cytotoxicity to tumour cells, also of neuroectodermal origin.Type: GrantFiled: May 10, 2002Date of Patent: September 11, 2007Assignee: Universita' Degli Studi di PadovaInventors: Giorgio Palu, Modesto Carli, Teresa Pecere, Giuseppe Zagotto
-
Publication number: 20070208079Abstract: The present invention relates to the use of certain novel myriceric acid derivatives of the formula: which are inhibitors of nuclear factor kappa B (NF-?B) and inhibit the activity of the endothelin receptor for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an NF-?B inhibitor and an endothelin receptor inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.Type: ApplicationFiled: March 1, 2007Publication date: September 6, 2007Applicant: SaviPu PharmaceuticalsInventors: Inderjit Kumar Dev, Ven Subbiah
-
Patent number: 7265220Abstract: Compound of formula (I): wherein: R1 represents aryl, heteroaryl or alkyl which is optionally substituted, or a group of formula —(CO)—CR6R7NR8R9 wherein R6, R7, R8 and R9 are as defined in the description, R2 represents hydrogen or alkyl, R3 represents hydrogen or optionally substituted alkyl, R4 represents a saturated or unsaturated, 7- to 15-membered bicyclic system or optionally substituted alkyl, or R3 and R4, together with the carbon atom carrying them, form a saturated or unsaturated, 3- to 18-membered, mono-, bi- or tri-cyclic system optionally containing one or more hetero atoms selected from O, S and N and optionally substituted, n represents 1 or 2, Ar represents aryl or heteroaryl, R5 represents amino, guanidino, cyano or amidino which is optionally substituted, its optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in pathological conditions involving activated protein C.Type: GrantFiled: February 17, 2003Date of Patent: September 4, 2007Assignee: Les Laboratories ServierInventors: Guillaume De Nanteuil, Philippe Gloanec, Tony Verbeuren, Alain Rupin
-
Patent number: 7196115Abstract: The present invention relates to the bioactivity of taxanes isolated from the leaves of Himalayan Yew tree Taxus wallichiana against human cancer cell lines grown in-vitro and subsequent identification of brevifoliol [1] as anticancer agent useful in the treatment of various types of cancer in humansType: GrantFiled: December 30, 2002Date of Patent: March 27, 2007Assignee: Council of Scientific and Industrial ResearchInventors: Suman Preet Singh Khanuja, Ranganathan Santha Kumar Tirupadiripuliyur, Ankur Garg, Raghvendra Kumar Mishra, Sunil Kumar Chattopadhyay, Sachin Srivastava, Arvind Singh Negi
-
Patent number: 7160865Abstract: Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.Type: GrantFiled: March 28, 2003Date of Patent: January 9, 2007Inventors: Theodore J. Lampidis, Waldemore Priebe